Seer, Inc. is quietly dominating the proteomics space despite a slight revenue dip—thanks to over $209 million in cash, aggressive stock buybacks, and 95+ scientific publications validating their Proteograph platform. Their deep, unbiased protein detection (measuring 3,400+ proteins where competitors fall short) is fueling AI-driven breakthroughs in multi-cancer screening and drug discovery. With key patent wins in the U.S. and Europe, strong IP protection, and new partnerships like Mayo Clinic, Seer’s leadership remains bullish on full-year growth, betting that science will soon outpace skepticism.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
